Skip to main content
UniHealth

Doctor search

Supriya Sham Vaidya, NP

Nurse Practitioner · New York

NPI 1740957778

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Office
1
Since medical school
4 years
Graduated 2022

Offices

1 location · Trustees of Columbia University in the City of New York · 2,262 clinicians in this group

Looking this up.

Hospitals listed: New York-Presbyterian Hospital. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Supriya Sham Vaidya’s office at (212) 305-9876 to ask if they take your plan before you enroll.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • New York-Presbyterian HospitalNew York, NYAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of New York Presbyterian Healthcare System, which runs 8 hospitalsHome of Herbert Irving Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 72% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 15.2 (13.8 to 16.7) · 1,897 cases, Jan 2024 – Dec 2024Better than the national rate — Abdominopelvic accidental puncture or laceration rate: 0.35 (0 to 0.86) · 10,364 cases, Jul 2022 – Jun 2024Better than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 0.4 (0.3 to 0.51), Jul 2022 – Jun 2024Better than the national rate — In-hospital fall-associated fracture rate: 0.14 (0.03 to 0.25) · 52,654 cases, Jul 2022 – Jun 2024Better than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 1.48 (0.6 to 2.36) · 14,926 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative acute kidney injury requiring dialysis rate: 0.48 (0 to 1.06) · 8,078 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative hemorrhage or hematoma rate: 0.94 (0.21 to 1.66) · 12,529 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 6.15 (4.51 to 7.79) · 8,277 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative sepsis rate: 1.66 (0.42 to 2.91) · 8,436 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.09 (0 to 0.3) · 44,511 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.575, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.632, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.22, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.743, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 3.6 (2.9 to 4.4) · 1,897 cases, Jan 2024 – Dec 2024Better than the national rate — Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies): 10.6 (8.9 to 12.6) · 7,950 cases, Jan 2022 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.6 (0.6 to 0.7) · 4,225 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for New York-Presbyterian Hospital

Behind the star rating — Deaths: 6 better, 2 the same, 0 worse of 8 measures. Safety: 4 better, 4 the same, 0 worse of 8 measures. Readmissions: 3 better, 6 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at New York-Presbyterian Hospital
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits15.2 (13.8 to 16.7) · 1,897 casesWorseJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.35 (0 to 0.86) · 10,364 casesBetterJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.4 (0.3 to 0.51)BetterJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.14 (0.03 to 0.25) · 52,654 casesBetterJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths1.48 (0.6 to 2.36) · 14,926 casesBetterJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.48 (0 to 1.06) · 8,078 casesBetterJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths0.94 (0.21 to 1.66) · 12,529 casesBetterJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths6.15 (4.51 to 7.79) · 8,277 casesBetterJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths1.66 (0.42 to 2.91) · 8,436 casesBetterJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.09 (0 to 0.3) · 44,511 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.575BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.632BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.22BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0.743BetterOct 2024 – Sep 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits3.6 (2.9 to 4.4) · 1,897 casesBetterJan 2024 – Dec 2024
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits10.6 (8.9 to 12.6) · 7,950 casesBetterJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.6 (0.6 to 0.7) · 4,225 casesBetterJan 2024 – Dec 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths156.83 (135.92 to 177.74) · 798 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.7 · 382 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths5.7 · 574 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.6 · 616 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.9 · 2,532 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.9 · 3,140 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths7.7 · 1,821 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths1.8 · 24,470 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.11 (0 to 0.22) · 48,588 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths0.84 (0 to 1.9) · 3,187 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4 · 1,240 casesNoneApr 2023 – Mar 2025
SSI - Abdominal HysterectomyInfections0.314No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.717No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.6 · 1,045 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.4 · 5,234 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits11 · 686 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits3 · 2,938 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits13.4 · 3,258 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.4 · 5,005 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits5.5 · 1,230 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.9 · 411 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.6 · 1,226 casesNoneJul 2023 – Jun 2025

What patients said (2,640 patients answered, 20% of those asked)

Patient survey stars by topic at New York-Presbyterian Hospital
Cleanliness3
Nurse communication3
Doctor communication3
Communication about medicines3
Discharge information3
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at New York-Presbyterian Hospital
Room was "always" clean65%
Nurses "always" communicated well76%
Doctors "always" communicated well78%
Staff "always" explained59%
Yes, staff "did" give patients this information85%
Yes, staff "did" give patients information about help after discharge84%
Doctors "always" explained things so they could understand74%
Doctors "always" listened carefully77%
Doctors "always" treated them with courtesy and respect84%
Patients who gave a rating of "9" or "10" (high)69%
Staff "always" explained new medications74%
Nurses "always" explained things so they could understand73%
Nurses "always" listened carefully72%
Nurses "always" treated them with courtesy and respect82%
"Always" quiet at night49%
"YES", patients would definitely recommend the hospital72%
Staff "always" explained possible side effects45%
Yes, staff "did" give patients information about possible symptoms87%

Original Medicare doctor bills

$12,632

Medicare paid this office $12,632 for 68 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)38$6,509$130
Return visit (30+ min)36$3,701$86
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's58$944$12

Who their Medicare patients are

68 Original Medicare patients in 2024. Average age 70 · Women 40% · Also on Medicaid 28% · Health risk score 2.90. Sicker patients than 9 in 10 peers; the typical nurse practitioner clinician is at 1.42.

Conditions among them: High blood pressure 71% · Chronic kidney disease 38% · Diabetes 34% · Coronary heart disease 34% · Depression 31% · Cancer 22% · Heart failure 21% · Atrial fibrillation 21%.

The office billed $75,388, Medicare allowed $16,575 and paid $12,632; for 190 services of 5 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202468190702.90$75,388$12,632
202352102742.14$53,565$9,718
20223040751.80$21,440$4,009

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 2 services

Original Medicare services billed in 2023
Return visit (30+ min)37$6,204$97
Short return visit (20+ min)15$1,207$67

2022: 1 service

Original Medicare services billed in 2022
Return visit (30+ min)19$2,014$101

Drugs they prescribed that Part D paid

$3,003,764

Pharmacies billed $3,003,764 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

388 generic and fewer than 11 brand-name prescriptions · $3,003,764 in drug cost · 27 antibiotic prescriptions to 15 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Brukinsa84$1,253,033$14,917
Jaypirca25$560,291$22,412
Rezurock12$422,777$35,231
Calquence15$325,890$21,726
Entecavir25$10,340$414
See all 13 drugs
Every Part D drug this clinician prescribed
Brukinsa84$1,253,033$14,917
Jaypirca25$560,291$22,412
Rezurock12$422,777$35,231
Calquence15$325,890$21,726
Entecavir25$10,340$414
Valacyclovir86$4,025$47
Gabapentin18$279$15
Famotidine29$213$7
Ondansetron Odt17$122$7
Pantoprazole21$119$6
Metoclopramide13$90$7
Sulfamethoxazole-Trimethoprim21$72$3
Prednisone19$22$1

Year by year

Part D prescribing by year
2024573110NoneNone$3,003,764
202338093NoneNone$1,081,232
2022625125NoneNone$1,549,091
202124170% (0)None$15,461

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 8 drugs

Part D drugs prescribed in 2023
Brukinsa34$505,652$14,872
Entecavir18$9,728$540
Valacyclovir67$5,553$83
Mirtazapine13$1,015$78
Pantoprazole14$287$21
Prednisone23$102$4
Famotidine15$90$6
Sulfamethoxazole-Trimethoprim15$83$6

2022: 17 drugs

Part D drugs prescribed in 2022
Imbruvica46$676,958$14,716
Brukinsa23$355,649$15,463
Calquence15$217,298$14,487
Zarxio13$36,368$2,798
Entecavir28$12,677$453
Valacyclovir115$7,772$68
Fluconazole26$1,865$72
Acyclovir24$1,008$42
Ondansetron Odt24$674$28
Pantoprazole16$426$27
Sulfamethoxazole-Trimethoprim54$395$7
Bupropion Hcl Sr11$291$26
Omeprazole19$282$15
Allopurinol16$137$9
Prednisone35$120$3
Ondansetron21$118$6
Metoclopramide11$37$3

Money from drug and device companies

$464 in 2025

Industry payments by year
2025714None$464
2024510None$434
202356None$135
2022827None$352

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
AbbvieEpkinly$148
3 payments
  • Meals for Epkinly · 2025-11-06 · $101
  • Meals for Epkinly · 2025-09-05 · $26
  • Meals for Epkinly · 2025-08-25 · $21
AstraZeneca Pharmaceuticals LPCalquence$120
2 payments
  • Education · 2025-05-06 · $95
  • Meals for Calquence · 2025-04-08 · $25
Adaptive BiotechnologiesClonoseq$84
4 payments
  • Meals for Clonoseq · 2025-12-11 · $20
  • Meals for Clonoseq · 2025-08-27 · $23
  • Meals for Clonoseq · 2025-05-08 · $25
  • Meals for Clonoseq · 2025-01-28 · $17
PfizerAdcetris$34
2 payments
  • Meals for Adcetris · 2025-07-23 · $18
  • Meals for Adcetris · 2025-03-19 · $16
Sanofi-Aventis U.S.Rezurock$28
1 payment
  • Meals for Rezurock · 2025-05-21 · $28
Novartis PharmaceuticalsFabhalta$27
1 payment
  • Meals for Fabhalta · 2025-04-07 · $27
See all 14 published payments
Every published payment
Adaptive BiotechnologiesMeals · 2025-12-11Clonoseq$20
AbbvieMeals · 2025-11-06Epkinly$101
AbbvieMeals · 2025-09-05Epkinly$26
Adaptive BiotechnologiesMeals · 2025-08-27Clonoseq$23
AbbvieMeals · 2025-08-25Epkinly$21
PfizerMeals · 2025-07-23Adcetris$18
Genmab U.S.Meals · 2025-06-11Epkinly$22
Sanofi-Aventis U.S.Meals · 2025-05-21Rezurock$28
Adaptive BiotechnologiesMeals · 2025-05-08Clonoseq$25
AstraZeneca Pharmaceuticals LPEducation · 2025-05-06None$95
AstraZeneca Pharmaceuticals LPMeals · 2025-04-08Calquence$25
Novartis PharmaceuticalsMeals · 2025-04-07Fabhalta$27
PfizerMeals · 2025-03-19Adcetris$16
Adaptive BiotechnologiesMeals · 2025-01-28Clonoseq$17
See earlier years (2024, 2023, 2022)

2024: $434

Payments by company in 2024
AstraZeneca Pharmaceuticals LPCalquence$223
4 payments
  • Meals · 2024-12-07 · $135
  • Meals for Calquence · 2024-10-09 · $29
  • Meals for Calquence · 2024-07-10 · $28
  • Meals for Calquence · 2024-01-10 · $31
IncyteNone$99
1 payment
  • Education · 2024-08-23 · $99
Adaptive BiotechnologiesClonoseq$67
3 payments
  • Meals for Clonoseq · 2024-11-15 · $20
  • Meals for Clonoseq · 2024-08-27 · $20
  • Meals for Clonoseq · 2024-05-14 · $27
AbbvieEpkinly$24
1 payment
  • Meals for Epkinly · 2024-09-03 · $24
Recordati Rare Diseases Inc.Sylvant$22
1 payment
  • Meals for Sylvant · 2024-06-21 · $22

2023: $135

Payments by company in 2023
Adaptive BiotechnologiesClonoseq$50
2 payments
  • Meals for Clonoseq · 2023-08-18 · $25
  • Meals for Clonoseq · 2023-01-27 · $25
Pharmacyclics LLC An AbbVieEpkinly$28
1 payment
  • Meals for Epkinly · 2023-05-25 · $28
Ipsen BiopharmaceuticalsTazverik$24
1 payment
  • Meals for Tazverik · 2023-08-08 · $24
SeagenAdcetris$18
1 payment
  • Meals for Adcetris · 2023-01-20 · $18
IncyteMonjuvi$16
1 payment
  • Meals for Monjuvi · 2023-05-16 · $16

2022: $352

Payments by company in 2022
SeagenAdcetris$125
1 payment
  • Meals for Adcetris · 2022-11-29 · $125
Novartis PharmaceuticalsPromacta$68
4 payments
  • Meals for Scemblix · 2022-10-19 · $14
  • Meals for Scemblix · 2022-10-14 · $16
  • Meals for Promacta · 2022-08-05 · $21
  • Meals for Promacta · 2022-07-07 · $17
Adaptive BiotechnologiesClonoseq$45
2 payments
  • Meals for Clonoseq · 2022-09-16 · $23
  • Meals for Clonoseq · 2022-09-09 · $22
Taiho OncologyInqovi$27
1 payment
  • Meals for Inqovi · 2022-10-07 · $27
Janssen BiotechImbruvica$25
1 payment
  • Meals for Imbruvica · 2022-11-29 · $25
Daiichi SankyoInjectafer$24
1 payment
  • Meals for Injectafer · 2022-12-06 · $24
CelgeneReblozyl$21
1 payment
  • Meals for Reblozyl · 2022-11-04 · $21
MorphoSys USMonjuvi$17
1 payment
  • Meals for Monjuvi · 2022-05-24 · $17

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
100.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1740957778
Licence
NY 347695
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Nurse practitioner (363L00000X); Federal specialty code 363LF0000X (363LF0000X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2021-08-26
NPI last updated
2026-06-30
NPI record certified
2026-06-30

This is when the NPI record was last certified, not a medical board exam.